SDC Table 5. Sub-group analysis for probiotic efficacy for the reduction of the duration of diarrhea.

Sub-groups	***S. boulardii* CNCM I-745**			***L. rhamnosus* GG**			***B. clausii* O/C,SIN, N/R, T**		
	SMD (95% C.I.	**P value**	**I^2**	**SMD (95% C.I.**	**P-value**	**I^2**	**SMD (95% C.I.**	**P-value**	**I^2**
Population:									
inpatient/mixed	-1.99 (-3.09, -0.90)	<0.001	97.1%	-0.97 (-1.94, 0.00)	0.050	98.7%	-1.39 (-2.74, -0.04)	<0.001	97.3%
outpatient	-1.18 (-1.69, -0.67)	<0.001	nd	-2.86 (-6.34, 0.61)	0.11	99.2%	na	na	na
Daily probiotic dose:									
Low dose	na	na	na	-0.24 (-0.92, 0.43)	0.48	94.5%	-2.00 (-2.59, -1.41)	<0.001	nd
High dose	-1.85 (-2.80, -0.91)	<0.001	96.5%	-2.36 (-3.57, -1.15)	<0.001	98.4%	-1.19 (-2.85, 0.47)	0.16	97.9%
Risk of Bias:									
High risk	-0.62 (-1.74, 0.51)	0.28	93.3%	-3.59 (-4.38, -2.79)	<0.001	nd	-1.19 (-2.85, 0.47)	0.16	97.9%
Low risk	-2.45 (-3.87, -1.03)	0.001	97.5%	-1.46 (-2.48, -0.44)	0.005	98.9%	na	na	na
Adequate blinding:									
Open controls	-1.98 (-3.42, -0.53)	0.007	96.8%	-4.33 (-5.73, -2.93)	<0.001	87.9%	-1.39 (-2.74, -0.04)	0.04	97.3%
Placebo	-1.76 (-3.33, -0.20)	0.03	97.2%	-0.78 (-1.61, 0.05)	0.07	98.4%	na	na	na
Zinc given:									
Yes	-2.05 (-3.36, -0.75)	0.002	96.4%	-5.02 (-5.59, -4.45)	<0.001	nd	-1.79 (-3.63, 0.05)	0.06	97.9%
No	-1.65 (-3.39, 0.08)	0.062	97.4%	-1.20 (-2.03, -0.37)	0.005	98.3%	na	na	na

Notes: Dose, low dose ($<10^{10}$/day for *S. boulardii* and *L. rhamnosus* GG or 2 x 10^9/d for *B. clausii* mix); high dose ($\geq 10^{10}$/day for *S. boulardii* and *L. rhamnosus* GG or 4 x 10^9/day for *B. clausii* mix).

Abbreviations: B., *Bacillus*; C.I., confidence interval; HDI, human development index (0.6, medium; 0.8 high); I^2, percent heterogeneity L., *Lactobacillus*; na, not applicable as no trials in category or missing data; nd, not determined as only one trial in category; S., *Saccharomyces*